Baseline characteristics
| Number (%) . | All patients (N = 111) . | ASCT (N = 69) . | CART (N = 42) . | P . |
|---|---|---|---|---|
| Diffuse LBCL/high-grade B-cell lymphoma | 75 (68) | 45 (65) | 30 (71) | .54 |
| Age >60 y | 47 (42) | 27 (39) | 20 (48) | .43 |
| Males | 78 (70) | 49 (71) | 29 (69) | .83 |
| European Cooperative Oncology Group performance status 2-4 | 14 (13) | 6 (9) | 8 (19) | .14 |
| Stage III-IV | 56 (50) | 22 (32) | 34 (81) | < .001∗ |
| Extranodal >1 | 24 (22) | 5 (7) | 19 (45) | < .001∗ |
| High lactate dehydrogenase | 59 (53) | 38 (55) | 21 (50) | .70 |
| IPI 3-5 | 31 (28) | 14 (20) | 17 (40) | .03∗ |
| Therapies >2 | 63 (57) | 27 (39) | 36 (86) | < .001∗ |
| Refractory | 49 (44) | 19 (28) | 30 (71) | < .001∗ |
| Number (%) . | All patients (N = 111) . | ASCT (N = 69) . | CART (N = 42) . | P . |
|---|---|---|---|---|
| Diffuse LBCL/high-grade B-cell lymphoma | 75 (68) | 45 (65) | 30 (71) | .54 |
| Age >60 y | 47 (42) | 27 (39) | 20 (48) | .43 |
| Males | 78 (70) | 49 (71) | 29 (69) | .83 |
| European Cooperative Oncology Group performance status 2-4 | 14 (13) | 6 (9) | 8 (19) | .14 |
| Stage III-IV | 56 (50) | 22 (32) | 34 (81) | < .001∗ |
| Extranodal >1 | 24 (22) | 5 (7) | 19 (45) | < .001∗ |
| High lactate dehydrogenase | 59 (53) | 38 (55) | 21 (50) | .70 |
| IPI 3-5 | 31 (28) | 14 (20) | 17 (40) | .03∗ |
| Therapies >2 | 63 (57) | 27 (39) | 36 (86) | < .001∗ |
| Refractory | 49 (44) | 19 (28) | 30 (71) | < .001∗ |
bold indicates statistically significant (p ≤ 0.05).